Ability of baclofen to prevent somatic manifestations and neurochemical changes during nicotine withdrawal

Drug and Alcohol Dependence

Volumn 119, Issue 1-2, 2011, Pages

  Varani, Andrés P ^a,b   Moutinho, Lirane Machado ^b   Calvo, Mariela ^b   Balerio, Graciela N ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Instituto de Investigaciones Farmacologicas   (Argentina)

Author keywords

Baclofen; GABAergic system; Mice; Nicotine; Withdrawal

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; BACLOFEN; DOPAMINE; MECAMYLAMINE; NICOTINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACTIVITY; GLOBAL SCORE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; MALE; METABOLITE; MOUSE; NICOTINE WITHDRAWAL SYNDROME; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSOMATIC DISORDER; SCORING SYSTEM; SMOKING CESSATION; SYMPTOMATOLOGY; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ANIMALS; BACLOFEN; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; MALE; MECAMYLAMINE; MICE; MOTOR ACTIVITY; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

MUS; NICOTIANA TABACUM;

EID: 80055009339     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.05.017     Document Type: Article

References (48)

1. Anthony J.C., Warner L.A., Kessler R.C. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp. Clin. Psychopharmacol. 1994, 2:244-268.
2. Balerio G.N., Rubio M.C. Baclofen analgesia: involvement of the GABAergic system. Pharmacol. Res. 2002, 46:281-286.
3. Balerio G.N., Aso E., Berrendero F., Murtra P., Maldonado R. Δ9-Tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur. J. Neurosci. 2004, 20:2737-2748.
4. Barik J., Wonnacott S. Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal. Mol. Pharmacol. 2006, 69:618-628.
5. Berrendero F., Kieffer L.B., Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in μ-opioid receptor knock-out mice. J. Neurosci. 2002, 22:10935-10940.
6. Biala G., Weglinska B. Blockade of the expression of mecamylamine-precipitated nicotine withdrawal by calcium channel antagonists. Pharmacol. Res. 2005, 51:483-488.
7. Biala G., Budzyńska B., Kruk M. Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice. Pharmacol. Res. 2005, 57:755-760.
8. Carboni E., Bortone L., Giua C., Di Chiara G. Dissociation of physical abstinence signs from changes in extracellular dopamine in the nucleus accumbens and in the prefrontal cortex of nicotine dependent rats. Drug Alcohol Depend. 2000, 58:93-102.
9. Castañé A., Valjent E., Ledent C., Parmentier M., Maldonado R., Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 2002, 43:857-867.
10. Colombo G., Agabio R., Carai M.A.M., Lobina C., Pani M., Reali R., Addolorato G., Gessa G.L. Ability of baclofen in reducing alcohol intake and withdrawal severity. I Preclinical evidence. Alcohol. Clin. Exp. Res. 2000, 24:58-66.
11. Corrigall W.A., Coen K.M., Adamson K.L., Chow J.Z. Response of nicotine self-administration in the rat to manipulations of mu-opioid and γ-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berl.) 2000, 149:107-114.
12. Cousins M.S., Stamat H.M., de Wit H. Effects of d-amphetamine and the GABA(B) receptor agonist baclofen on cigarette smoking and nicotine craving. College on Problems of Drug Dependence. 62nd Annual Meeting 2000, 32.
13. Diaz S.L., Kemmling A.K., Rubio M.C., Balerio G.N. Lack of sex-related differences in the prevention by baclofen of the morphine withdrawal syndrome in mice. Behav. Pharmacol. 2001, 12:75-79.
14. Diaz S.L., Kemmling A.K., Balerio G.N. Baclofen reestablishes striatal and cortical dopamine concentrations during naloxone-precipitated withdrawal. Neurochem. Int. 2003, 42:293-298.
15. Diaz S.L., Kemmling A.K., Bonavita C.D., Rubio M.C., Balerio G.N. Baclofen reestablishes micro-opioid receptor levels modified by morphine withdrawal syndrome in either sex. Synapse 2004, 54:24-29.
16. Diaz S.L., Barros V.G., Antonelli M.C., Rubio M.C., Balerio G.N. Morphine withdrawal syndrome and its prevention with baclof autoradiographic study of mu-opioid receptors in prepubertal male female mice. Synapse 2006, 60:132-140.
17. Erhardt S., Hajos M., Lindberg A., Engberg G. Nicotine-induced excitation of locus coeruleus neurons is blocked by elevated levels of endogenous kynurenic acid. Synapse 2000, 37:104-108.
18. Erhardt S., Mathé J.M., Chergui K., Engberg G., Svensson T.H. GABA(B) receptor-mediated modulation of the firing pattern of ventral tegmental area dopamine neurons in vivo. Naunyn Schmiedebergs Arch. Pharmakol. 2002, 365:173-180.
19. Fadda P., Scherma M., Fresu A., Collu M., Fratta W. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 2003, 50:1-6.
20. Fattore L., Spano M.S., Cossu G., Scherma M., Fratta W., Fadda P. Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents. Eur. Neuropsychopharmacol. 2009, 19:487-498.
21. File S.E., Zarkovsky A., Gulati K. Effects of baclofen and nitrendipine on ethanol withdrawal responses in the rat. Neuropharmacology 1991, 30:183-190.
22. Franklin T.R., Harper D., Kampman K., Kildea-McCrea S., Jens W., Lynch K.G., O'Brien C.P., Childress A.R. The GABAB agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend. 2009, 103:30-36.
23. Fung Y.K., Schimid M.J., Anderson T.M., Lau Y. Effects of nicotine withdrawal on central dopaminergic systems. Pharmacol. Biochem. Behav. 1996, 53:635-640.
24. Gäddnäs H., Pietilä K., Ahtee L. Effects of chronic oral nicotine treatment and its withdrawal on locomotor activity and brain monoamines in mice. Behav. Brain Res. 2000, 113:65-72.
25. Guyton A.C. Sistema Nervioso Central: C. Neurofisiología motora e integradora. Anatomía Fisiología Del Sistema Nervioso 1994, Libermed Verlag, Editorial Panamericana, Uruguay, p. 301.
26. Haas A.L., Muñoz R.F., Humfleet G.L., Reus V.I., Hall S.M. Influences of mood, depression history and treatment modality on outcomes in smoking cessation. J. Consult. Clin. Psychol. 2004, 72:563-570.
27. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224:1451-1453.
28. Heinrichs S.C., Leite-Morris K.A., Carey R.J., Kaplan G.B. Baclofen enhances extinction of opiate conditioned place preference. Behav. Brain Res. 2010, 207:353-359.
29. Hildebrand B.E., Nomikos G.G., Hertel P., Schilström B., Svensson T.H. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res. 1998, 779:214-225.
30. Holstein S.E., Dobbs L., Phillips T.J. Attenuation of the stimulant response to ethanol is associated with enhanced ataxia for a GABA, but not a GABA, receptor agonist. Alcohol. Clin. Exp. Res. 2009, 33:108-120.
31. Kenny P.J., Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacol. Biochem. Behav. 2001, 70:531-549.
32. Koob G.F. Neural mechanisms of drug reinforcement. Ann. N. Y. Acad. Sci. 1992, 654:171-191.
33. Kota D., Martin B.R., Robinson S.E., Damaj M.I. Nicotine dependence and reward differ between adolescent and adult male mice. J. Pharmacol. Exp. Ther. 2007, 322:399-407.
34. Kuhar M.J., Couceyro P.R., Lambert P.D. Catecholamines. Basic Neurochemistry: Molecular, Cellular and Medical Aspects 1999, 243-261. Lippincott-Raven, Philadelphia, PA. G.J. Siegel, B.W. Agranoff, R. Wayne Albers, S.K. Fisher, M.D. Uhler (Eds.).
35. Le Foll B., Wertheim C.E., Goldberg S.R. Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats. Neurosci. Lett. 2008, 443:236-240.
36. Léna C., de Kerchove D'Exaerde A., Cordero-Erausquin M., Le Novère N., del Mar Arroyo-Jimenez M., Changeux J.P. Diversity and distribution of nicotinic acetylcholine receptors in the locus ceruleus neurons. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:12126-12131.
37. Mannucci C., Pieratti A., Firenzuoli F., Caputi A.P., Calapai G. Serotonin mediates beneficial effects of Hypericum perforatum on nicotine withdrawal signs. Phytomedicine 2007, 14:645-651.
38. Mansvelder H.D., McGehee D.S. Cellular and synaptic mechanisms of nicotine addiction. J. Neurobiol. 2002, 53:606-617.
39. Markou A. Review. Neurobiology of nicotine dependence. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2008, 163:3159-3168.
40. Mathieu-Kia A.M., Kellogg S.H., Butelman E.R., Kreek M.J. Nicotine addiction: insights from recent animal studies. Psychopharmacology (Berl.) 2002, 162:102-118.
41. Mueller A.L., Brodie M.S. Intracellular recording from putative dopamine-containing neurons in the ventral tegmental area of tsai in a brain slice preparation. J. Neurosci. Methods 1989, 28:15-22.
42. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997, 349:1498-1504.
43. Sandoval M.R., Palermo-Neto J. Central nervous system supersensitivity and withdrawal from long-term treatment with barbital. Neuropharmacology 1985, 12:1247-1251.
44. SENASA (Resolución 617/2002): Requisitos, condiciones y procedimientos para la habilitación técnica de laboratorios que posean bioterios de producción, mantenimiento y local de experimentación.
45. Slotkin T.A., Seidler F.J. A unique role for striatal serotonergic systems in the withdrawal from adolescent nicotine administration. Neurotoxicol. Teratol. 2007, 29:10-16.
46. Stolerman I.P., Jarvis M.J. The scientific case that nicotine is addictive. Psychopharmacology (Berl.) 1995, 117:2-10.
47. Watkins S.S., Stinus L., Koob G.F., Markou A. Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated. J. Pharmacol. Exp. Ther. 2000, 292:1053-1064.
48. Xi Z.X., Stein E.A. Nucleus accumbens dopamine release modulation by mesolimbic GABAA receptors-an in vivo electrochemical study. Brain Res. 1998, 798:156-165.